FDA Panel Rejects Experimental Stem Cell Therapy for ALS FDA Panel Rejects Experimental Stem Cell Therapy for ALS

An FDA advisory panel resoundingly rejected NurOwn, an experimental stem cell therapy for mild to moderate ALS.Medscape Medical News
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Neurology & Neurosurgery News Source Type: news